CELCUITY INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.92 USD | +0.95% |
|
-7.66% | +9.27% |
| Mar. 29 | Celcuity Inc. Enters into Second Amendment to its Existing Loan and Security Agreement | CI |
| Mar. 28 | Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating | MT |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the Celcuity Third Q...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.92
USD
Average target price
29.5
USD
Spread / Average Target
+85.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.27% | 485M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CELC Stock
- News Celcuity Inc.
- Transcript : Celcuity Inc., Q3 2023 Earnings Call, Nov 13, 2023
